Clinical Scorecard: Efficacy and Safety of Sequential Gemcitabine and Docetaxel in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of BCG-Naïve and BCG-Failure Patients

At a Glance

Key Highlights

• Pooled recurrence-free survival (RFS) at 12 months was 73.75%.
• BCG-naïve patients had significantly higher 12-month RFS (82.50%) compared to BCG-failure patients (60.00%).
• GEM/DOCE demonstrated high progression-free survival (95.57%) and overall survival (97.32%) at 12 months.
• Treatment-related adverse events occurred in 52.59% of patients, with a low intolerance rate of 3.55%.
• The evidence is limited by study heterogeneity and predominance of retrospective designs.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of NMIBC should include risk stratification based on tumor characteristics and prior BCG response.

Management

• Intravesical GEM/DOCE is recommended for high-risk NMIBC patients, particularly those who are BCG-naïve or have BCG-failure.

Monitoring & Follow-up

• Patients should be monitored for recurrence and treatment-related adverse events post-therapy.

Risks

• Consideration of treatment-related adverse events and overall treatment intolerance is essential.

Patient & Prescribing Data

Adult patients with high-risk and very high-risk NMIBC.

GEM/DOCE provides a viable alternative for patients with BCG treatment failure.

Clinical Best Practices

• Utilize risk stratification to guide treatment decisions in NMIBC.
• Consider GEM/DOCE for patients with inadequate response to BCG therapy.

Related Resources & Content

• Systematic Review Registration